Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)

Description

This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.

Conditions

Obesity, Bariatric Surgery, Sleeve Gastrectomy, Gastroesophageal Reflux Disease

Study Overview

Study Details

Study overview

This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.

Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With Vertical Sleeve Gastrectomy (INNOVATE-VSG)

Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Orange

University of California, Irvine, Orange, California, United States, 92628

San Diego

University of California, San Diego, San Diego, California, United States, 92093

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male and female subjects aged 18-60 years
  • 2. Body mass index (BMI) 35-50 kg/m2
  • 3. Must meet the BMI criteria before and after 6 months of nonsurgical weight management
  • 4. Presence of GERD defined for this trial as acid exposure time (AET) of 4.9% or above as assessed with the Bravo pH test.
  • 5. Have health insurance which pays for the costs of bariatric surgery and standard medical care before and after surgery
  • 6. Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry and prior to surgery
  • 7. Must be able to provide written informed consent
  • 1. Hiatal hernia \>2cm (defined as maximum axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at the time of surgery)
  • 2. Evidence of clinically significant major esophageal motility disorder as determined by the site primary investigator
  • 3. Severe gastroparesis
  • 4. Previous bariatric or anti-reflux procedure
  • 5. Barrett's esophagus
  • 6. Subjects requiring mesh treatment at time of procedure
  • 7. Severe heart (e.g., severe heart failure, unstable coronary artery disease), or end-stage lung disease as determined by the site primary investigator
  • 8. Subjects with pacemakers, implantable defibrillators, neurostimulators
  • 9. Portal hypertension or cirrhosis
  • 10. Chronic pancreatitis
  • 11. Active cancer treatment
  • 12. Inability to tolerate general anesthesia
  • 13. Uncontrollable coagulopathy
  • 14. Significant and uncontrolled inflammatory bowel disease
  • 15. Severe and/or uncontrolled psychiatric disorder (including psychosis, bipolar disorder) as determined during standard pre-surgery psychiatric screening at the site.
  • 16. Suicidal ideation or unstable/untreated major depressive disorder within the past year
  • 17. Alcohol or substance use disorder within the past year.
  • 18. Pregnant or breastfeeding or planning pregnancy in the coming 24 months
  • 19. Diminished intellectual capacity to consent or follow pre- and post-surgery instructions
  • 20. History of, or any current health condition that, in the opinion of the PI, would make the subject ineligible for sleeve gastrectomy, or put the subject at risk by participation in the study.

Ages Eligible for Study

18 Years to 60 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Irvine,

Ninh T. Nguyen, MD, PRINCIPAL_INVESTIGATOR, University of California, Irvine

Ravinder K. Mittal, MD, PRINCIPAL_INVESTIGATOR, University of California, San Diego

Study Record Dates

2027-07-31